Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
generation 2.5 microRNA-22-3p antagomir
- Development stage
- Preclinical
- Lead developer
- AptamiR Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
The generation 2.5 microRNA-22-3p antagomir is a peptide nucleic acid (PNA)-based antisense oligonucleotide developed by AptamiR Therapeutics for the treatment of metabolic diseases. It specifically targets and antagonizes miR-22-3p, a microRNA that plays a key role in regulating lipid metabolism, thermogenesis, and insulin sensitivity. To enhance delivery and potency, these compounds are conjugated to either a fatty acid (such as C32:6 dotriacontahexaenoic acid) or a short peptide (such as hexarelin), which facilitates active uptake into adipocytes via the FAT/CD36 (Fatty Acid Translocase) transporter. This targeted delivery strategy is designed to improve the safety profile and reduce the required dose compared to earlier generations. The drug is currently in IND-enabling preclinical development for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD/MASH).
- Other names
- miR-22-3p antagomir (generation 2.5)
02
Targets
CD36 (CD36 antigen)miR-22-3p (MicroRNA 22-3p)
Beyond the preview
Go deeper on generation 2.5 microRNA-22-3p antagomir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on generation 2.5 microRNA-22-3p antagomir.